Improved survival in multiple myeloma and the impact of novel therapies

Shaji K Kumar, S Vincent Rajkumar, Angela Dispenzieri, Martha Lacy, Suzanne R. Hayman, Francis K. Buadi, Steven R. Zeldenrust, David M Dingli, Stephen J Russell, John A. Lust, Philip R. Greipp, Robert A. Kyle, Morie Gertz

Research output: Contribution to journalArticle

1572 Citations (Scopus)

Abstract

Treatments for myeloma have expanded in the last decade, but it is not clear if the introduction of novel therapies and the increased use of high-dose therapy have translated into better outcome for patients with myeloma. We examined the outcome of 2 groups of patients seen at a single institution, one from time of diagnosis and the other from the time of relapse, to examine the survival trends over time. Among 387 patients relapsing after stem- cell transplantation, a clear improvement in overall survival from the time of relapse was seen, with those relapsing after 2000 having a median overall survival of 23.9 versus 11.8 months (P <.001) for those who relapsed prior to this date. This improvement was independent of other prognostic factors. Patients treated with one or more of the newer drugs (thalidomide, lenalidomide, bortezomib) had longer survival from relapse (30.9 vs 14.8 months; P <.001). In a larger group of 2981 patients with newly diagnosed myeloma, those diagnosed in the last decade had a 50% improvement in overall survival (44.8 vs 29.9 months; P <.001). In this study, we demonstrate improved outcome of patients with myeloma in recent years, both in the relapsed setting as well as at diagnosis.

Original languageEnglish (US)
Pages (from-to)2516-2520
Number of pages5
JournalBlood
Volume111
Issue number5
DOIs
StatePublished - Mar 1 2008

Fingerprint

Multiple Myeloma
Thalidomide
Survival
Stem cells
Recurrence
Therapeutics
Pharmaceutical Preparations
Stem Cell Transplantation
Bortezomib
lenalidomide

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Improved survival in multiple myeloma and the impact of novel therapies. / Kumar, Shaji K; Rajkumar, S Vincent; Dispenzieri, Angela; Lacy, Martha; Hayman, Suzanne R.; Buadi, Francis K.; Zeldenrust, Steven R.; Dingli, David M; Russell, Stephen J; Lust, John A.; Greipp, Philip R.; Kyle, Robert A.; Gertz, Morie.

In: Blood, Vol. 111, No. 5, 01.03.2008, p. 2516-2520.

Research output: Contribution to journalArticle

Kumar, Shaji K ; Rajkumar, S Vincent ; Dispenzieri, Angela ; Lacy, Martha ; Hayman, Suzanne R. ; Buadi, Francis K. ; Zeldenrust, Steven R. ; Dingli, David M ; Russell, Stephen J ; Lust, John A. ; Greipp, Philip R. ; Kyle, Robert A. ; Gertz, Morie. / Improved survival in multiple myeloma and the impact of novel therapies. In: Blood. 2008 ; Vol. 111, No. 5. pp. 2516-2520.
@article{765a1090174d4be0aa5d443b08d9fcbd,
title = "Improved survival in multiple myeloma and the impact of novel therapies",
abstract = "Treatments for myeloma have expanded in the last decade, but it is not clear if the introduction of novel therapies and the increased use of high-dose therapy have translated into better outcome for patients with myeloma. We examined the outcome of 2 groups of patients seen at a single institution, one from time of diagnosis and the other from the time of relapse, to examine the survival trends over time. Among 387 patients relapsing after stem- cell transplantation, a clear improvement in overall survival from the time of relapse was seen, with those relapsing after 2000 having a median overall survival of 23.9 versus 11.8 months (P <.001) for those who relapsed prior to this date. This improvement was independent of other prognostic factors. Patients treated with one or more of the newer drugs (thalidomide, lenalidomide, bortezomib) had longer survival from relapse (30.9 vs 14.8 months; P <.001). In a larger group of 2981 patients with newly diagnosed myeloma, those diagnosed in the last decade had a 50{\%} improvement in overall survival (44.8 vs 29.9 months; P <.001). In this study, we demonstrate improved outcome of patients with myeloma in recent years, both in the relapsed setting as well as at diagnosis.",
author = "Kumar, {Shaji K} and Rajkumar, {S Vincent} and Angela Dispenzieri and Martha Lacy and Hayman, {Suzanne R.} and Buadi, {Francis K.} and Zeldenrust, {Steven R.} and Dingli, {David M} and Russell, {Stephen J} and Lust, {John A.} and Greipp, {Philip R.} and Kyle, {Robert A.} and Morie Gertz",
year = "2008",
month = "3",
day = "1",
doi = "10.1182/blood-2007-10-116129",
language = "English (US)",
volume = "111",
pages = "2516--2520",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "5",

}

TY - JOUR

T1 - Improved survival in multiple myeloma and the impact of novel therapies

AU - Kumar, Shaji K

AU - Rajkumar, S Vincent

AU - Dispenzieri, Angela

AU - Lacy, Martha

AU - Hayman, Suzanne R.

AU - Buadi, Francis K.

AU - Zeldenrust, Steven R.

AU - Dingli, David M

AU - Russell, Stephen J

AU - Lust, John A.

AU - Greipp, Philip R.

AU - Kyle, Robert A.

AU - Gertz, Morie

PY - 2008/3/1

Y1 - 2008/3/1

N2 - Treatments for myeloma have expanded in the last decade, but it is not clear if the introduction of novel therapies and the increased use of high-dose therapy have translated into better outcome for patients with myeloma. We examined the outcome of 2 groups of patients seen at a single institution, one from time of diagnosis and the other from the time of relapse, to examine the survival trends over time. Among 387 patients relapsing after stem- cell transplantation, a clear improvement in overall survival from the time of relapse was seen, with those relapsing after 2000 having a median overall survival of 23.9 versus 11.8 months (P <.001) for those who relapsed prior to this date. This improvement was independent of other prognostic factors. Patients treated with one or more of the newer drugs (thalidomide, lenalidomide, bortezomib) had longer survival from relapse (30.9 vs 14.8 months; P <.001). In a larger group of 2981 patients with newly diagnosed myeloma, those diagnosed in the last decade had a 50% improvement in overall survival (44.8 vs 29.9 months; P <.001). In this study, we demonstrate improved outcome of patients with myeloma in recent years, both in the relapsed setting as well as at diagnosis.

AB - Treatments for myeloma have expanded in the last decade, but it is not clear if the introduction of novel therapies and the increased use of high-dose therapy have translated into better outcome for patients with myeloma. We examined the outcome of 2 groups of patients seen at a single institution, one from time of diagnosis and the other from the time of relapse, to examine the survival trends over time. Among 387 patients relapsing after stem- cell transplantation, a clear improvement in overall survival from the time of relapse was seen, with those relapsing after 2000 having a median overall survival of 23.9 versus 11.8 months (P <.001) for those who relapsed prior to this date. This improvement was independent of other prognostic factors. Patients treated with one or more of the newer drugs (thalidomide, lenalidomide, bortezomib) had longer survival from relapse (30.9 vs 14.8 months; P <.001). In a larger group of 2981 patients with newly diagnosed myeloma, those diagnosed in the last decade had a 50% improvement in overall survival (44.8 vs 29.9 months; P <.001). In this study, we demonstrate improved outcome of patients with myeloma in recent years, both in the relapsed setting as well as at diagnosis.

UR - http://www.scopus.com/inward/record.url?scp=41949130070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41949130070&partnerID=8YFLogxK

U2 - 10.1182/blood-2007-10-116129

DO - 10.1182/blood-2007-10-116129

M3 - Article

C2 - 17975015

AN - SCOPUS:41949130070

VL - 111

SP - 2516

EP - 2520

JO - Blood

JF - Blood

SN - 0006-4971

IS - 5

ER -